Straumann Group appoints Isabelle Adelt as Chief Financial Officer
Werte in diesem Artikel
Straumann Holding AG
/ Key word(s): Personnel
Werbung Werbung Basel, March 7, 2025: Straumann Group announces the appointment of Isabelle Adelt as Chief Financial Officer and Member of the Executive Management Board. Isabelle will join the Straumann Group on July 1, 2025, and will succeed Yang Xu. The Group announced last month that Yang Xu decided to leave the Straumann Group to pursue opportunities outside the company. Guillaume Daniellot, Chief Executive Officer, said: “I've had the pleasure of getting to know Isabelle as a dynamic finance leader with a strong ability to turn strategy into action. She has a proven track record of driving value, fostering diverse high-performing teams, and navigating complex international environments. Her passion for digitalization and sustainable growth makes her a fantastic addition to our management team. I’m excited to welcome her on board and look forward to working closely together.” Werbung Werbung Isabelle Adelt joins Straumann Group from the publicly listed FUCHS SE Group in Germany, the world’s largest independent lubricant manufacturer, where she is Chief Financial Officer and Executive Board member since 2022. With over 15 years of international leadership experience, she has deep expertise in finance, management consulting, and private equity. Before FUCHS SE, Isabelle held key financial roles at Schenck Process, a Blackstone company, and also served as CFO of Zeiss Greater China. She began her career as a performance improvement consultant at Ernst & Young in Germany and has since worked in both publicly listed and family-run businesses, gaining extensive international experience in Germany, Poland, and China. Werbung Werbung Born in 1984, Isabelle is a German citizen and holds an MBA from the Bielefeld University, Germany. About Straumann Group The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss. Headquartered in Basel, Switzerland, the Group currently employs close to 12’000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.
Disclaimer This press release contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan," "goal," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group’s control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this document. Accordingly, you should not rely on any forward-looking statements contained in this press release. Important factors that could cause the Group’s expectations regarding future results, performance or achievements to differ materially from those expressed in a forward-looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this release as of the date it is issued and does not undertake any obligation to update any statements as a result of new information, future events or otherwise.This release constitutes neither an offer to sell nor a solicitation to buy any securities.
End of Media Release |
Language: | English |
Company: | Straumann Holding AG |
Peter Merian-Weg 12 | |
4052 Basel | |
Switzerland | |
Phone: | +41619651239 |
Fax: | +41 61 965 11 06 |
E-mail: | jana.erdmann@straumann.com |
Internet: | www.straumann-group.com |
ISIN: | CH1175448666 |
Valor: | 914326 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2096940 |
End of News | EQS News Service |
|
2096940 07.03.2025 CET/CEST
Ausgewählte Hebelprodukte auf Straumann
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Straumann
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Straumann Holding AG
Analysen zu Straumann Holding AG
Datum | Rating | Analyst | |
---|---|---|---|
27.02.2013 | Straumann verkaufen | Commerzbank AG | |
21.02.2013 | Straumann halten | Vontobel Research | |
18.02.2013 | Straumann halten | Vontobel Research | |
04.01.2013 | Straumann halten | Vontobel Research | |
10.12.2012 | Straumann kaufen | Die Actien-Börse |
Datum | Rating | Analyst | |
---|---|---|---|
10.12.2012 | Straumann kaufen | Die Actien-Börse | |
31.10.2012 | Straumann buy | Deutsche Bank AG | |
25.10.2011 | Straumann buy | Nomura | |
24.08.2011 | Straumann buy | Nomura | |
01.10.2008 | Straumann per Limit bei 180 EUR einsteigen | Der Aktionär |
Datum | Rating | Analyst | |
---|---|---|---|
21.02.2013 | Straumann halten | Vontobel Research | |
18.02.2013 | Straumann halten | Vontobel Research | |
04.01.2013 | Straumann halten | Vontobel Research | |
26.11.2012 | Straumann hold | Vontobel Research | |
26.11.2012 | Straumann neutral | Sarasin Research |
Datum | Rating | Analyst | |
---|---|---|---|
27.02.2013 | Straumann verkaufen | Commerzbank AG | |
01.11.2012 | Straumann underperform | Exane-BNP Paribas SA | |
30.10.2012 | Straumann underperform | Cheuvreux SA | |
25.10.2012 | Straumann underperform | Exane-BNP Paribas SA | |
27.08.2012 | Straumann reduce | Commerzbank Corp. & Markets |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Straumann Holding AG nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen